The expression of RET and its multiple splice forms in developing human kidney
- PMID: 9150387
- DOI: 10.1038/sj.onc.1201016
The expression of RET and its multiple splice forms in developing human kidney
Abstract
A series of inductive events between two different cell groups, the ureteric bud epithelium and metanephric mesenchyme, gives rise to the functional mammalian kidney. These reciprocal inductive interactions involve a number of molecules, one of which is the RET receptor tyrosine kinase. The phenotype of mice lacking functional RET includes kidney agenesis or severe dysgenesis, indicating a requirement for RET in kidney organogenesis. To investigate RET expression in human kidney development, we used a semi-quantitative RT-PCR-based strategy to examine a panel of kidney RNA samples ranging from 8-24 weeks gestational age. We found RET expression was highest earlier in development (14 weeks) with expression decreasing through to 24 weeks gestation. While three alternative RET transcripts generated by exon skipping at the 5' end of the gene were all detected throughout kidney development, expression of one transcript, RET2/6, where exon 2 was spliced to exon 6, varied relative to full length RET during this period. Levels of RET2/6 were highest at the earliest age of fetal kidney examined (8 weeks) and decreased relative to all other RET transcripts to low adult levels. The period of high expression coincides with a period of rapid bud bifurcation. Thus, it is possible that RET2/6 has a role in the early growth and differentiation of the human kidney.
Similar articles
-
Expression of RET 3' splicing variants during human kidney development.Oncogene. 1998 Feb 26;16(8):991-6. doi: 10.1038/sj.onc.1201622. Oncogene. 1998. PMID: 9519873
-
Comparative role of phosphotyrosine kinase domains of c-ros and c-ret protooncogenes in metanephric development with respect to growth factors and matrix morphogens.Dev Biol. 1996 Aug 25;178(1):133-48. doi: 10.1006/dbio.1996.0204. Dev Biol. 1996. PMID: 8812115
-
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas.Oncogene. 2001 Feb 15;20(7):885-92. doi: 10.1038/sj.onc.1204161. Oncogene. 2001. PMID: 11314023
-
The ret/PTC oncogene in papillary thyroid carcinoma.J Lab Clin Med. 1994 Mar;123(3):331-7. J Lab Clin Med. 1994. PMID: 8133143 Review. No abstract available.
-
Genetic control of kidney development.Adv Nephrol Necker Hosp. 1997;26:1-17. Adv Nephrol Necker Hosp. 1997. PMID: 8922122 Review. No abstract available.
Cited by
-
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16. Biochem Pharmacol. 2023. PMID: 37595672 Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget. 2016 Jun 14;7(24):36101-36114. doi: 10.18632/oncotarget.9137. Oncotarget. 2016. PMID: 27150058 Free PMC article.
-
Alternative splicing results in RET isoforms with distinct trafficking properties.Mol Biol Cell. 2012 Oct;23(19):3838-50. doi: 10.1091/mbc.E12-02-0114. Epub 2012 Aug 8. Mol Biol Cell. 2012. PMID: 22875993 Free PMC article.
-
Characterisation of the human GFRalpha-3 locus and investigation of the gene in Hirschsprung disease.J Med Genet. 2000 Sep;37(9):674-9. doi: 10.1136/jmg.37.9.674. J Med Genet. 2000. PMID: 10978357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
